Cargando…

Once-Daily Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults and Adolescents Aged 12 Years and Over: A Short Review of Current Clinical Perspectives

Atopic dermatitis (AD) is a chronic inflammatory skin disorder with high prevalence and a complex pathophysiology. This relapsing and remitting skin disorder has many negative consequences on the patient’s quality of life and that of his family. Until now, moderate-to-severe AD treatment was a sympt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Niculet, Elena, Bobeica, Carmen, Stefanopol, Ioana Anca, Pelin, Ana Maria, Nechifor, Alexandru, Onisor, Cristian, Tatu, Alin Laurentiu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014825/ https://www.ncbi.nlm.nih.gov/pubmed/35444421 http://dx.doi.org/10.2147/TCRM.S338661

Ejemplares similares

Hearing Loss Secondary to Systemic Sclerosis Vasculopathy: Case Study with a Short Review
por: Bobeica, Carmen, et al.
Publicado: (2022)

Abrocitinib 100 mg Once Daily for Moderate-to-Severe Atopic Dermatitis: A Review of Efficacy and Safety, and Expert Opinion on Use in Clinical Practice
por: Gooderham, Melinda J., et al.
Publicado: (2023)

Clinical, Imaging, Histological and Surgical Aspects Regarding Giant Paraovarian Cysts: A Systematic Review
por: Stefanopol, Ioana Anca, et al.
Publicado: (2022)

Multimodal Considerations Concerning Basal Cell Carcinoma Clefting – Profile of Structural and Aggressive Traits – Perspectives
por: Niculet, Elena, et al.
Publicado: (2022)

The Influence of Living in Rural Areas on the Evolution and Management of Pediatric Ovarian Cystic Lesions: A Retrospective Study on a Cohort from South Eastern Romania
por: Stefanopol, Ioana Anca, et al.
Publicado: (2022)

Diagnostic and Management of Undescended Ovary – A Preoperative Dilemma: A Case-Based Systematic Review
por: Stefanopol, Ioana Anca, et al.
Publicado: (2022)

Interrelationship and Sequencing of Interleukins4, 13, 31, and 33 – An Integrated Systematic Review: Dermatological and Multidisciplinary Perspectives
por: Tatu, Alin Laurentiu, et al.
Publicado: (2022)

CREST Syndrome in Systemic Sclerosis Patients – Is Dystrophic Calcinosis a Key Element to a Positive Diagnosis?
por: Bobeica, Carmen, et al.
Publicado: (2022)

Efficacy and safety of abrocitinib for moderate-to-severe atopic dermatitis in adolescents and adults: Meta-analysis
por: Li, Ling, et al.
Publicado: (2023)

Rare case of metachronous tumor: Nasopharyngeal and colorectal carcinoma
por: Jicman (Stan), Daniela, et al.
Publicado: (2021)

Basal Cell Carcinoma Perineural Invasion and Suggestive Signs of Perineural Invasion—Findings and Perspectives
por: Niculet, Elena, et al.
Publicado: (2023)

Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis
por: Iznardo, Helena, et al.
Publicado: (2023)

Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial
por: Silverberg, Jonathan I., et al.
Publicado: (2020)

Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis
por: Wojciechowski, Jessica, et al.
Publicado: (2022)

Paraclinical Aspects in Systemic Sclerosis
por: Bobeica, Carmen, et al.
Publicado: (2022)

Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate‐to‐severe atopic dermatitis: A network meta‐analysis
por: Wan, Huiying, et al.
Publicado: (2022)

Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
por: Nogueira, Miguel, et al.
Publicado: (2021)

Correction to: Population Pharmacokinetics of Abrocitinib in Healthy Individuals and Patients with Psoriasis or Atopic Dermatitis
por: Wojciechowski, Jessica, et al.
Publicado: (2022)

A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib
por: Zhao, Jiahui, et al.
Publicado: (2022)

Efficacy of abrocitinib for atopic dermatitis: a meta-analysis of randomized controlled trials
por: Zhang, Daojun, et al.
Publicado: (2021)

Glucocorticoid-Induced Skin Atrophy: The Old and the New
por: Niculet, Elena, et al.
Publicado: (2020)

Comparative Evaluation of the Clinical Severity of COVID-19 of Vaccinated and Unvaccinated Patients in Southeastern Romania in the First 6 Months of 2022, during the Omicron Wave
por: Manole, Corina, et al.
Publicado: (2023)

The Role of D-Dimers in the Initial Evaluation of COVID-19
por: Baroiu, Liliana, et al.
Publicado: (2022)

Benefits and adverse events of melatonin use in the elderly (Review)
por: Anghel, Lucreția, et al.
Publicado: (2022)

The Role of D-Dimers in the Initial Evaluation of COVID-19 [Response To Letter]
por: Baroiu, Liliana, et al.
Publicado: (2022)

Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial
por: Eichenfield, Lawrence F., et al.
Publicado: (2021)

Effectiveness and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
por: Fadlalmola, Hammad Ali, et al.
Publicado: (2021)

Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study
por: Alexis, Andrew, et al.
Publicado: (2022)

Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial
por: Gooderham, Melinda J., et al.
Publicado: (2022)

Patient‐reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate‐to‐severe atopic dermatitis
por: Thyssen, J.P., et al.
Publicado: (2021)

Efficacy and safety of abrocitinib and upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A systematic review and meta-analysis
por: Gao, Qin, et al.
Publicado: (2023)

Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib
por: Nezamololama, Novin, et al.
Publicado: (2020)

Some Manifestations of Tuberculosis in Otorhinolaryngology – Case Series and a Short Review of Related Data from South-Eastern Europe
por: Mocanu, Adela-Ioana, et al.
Publicado: (2022)

Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program
por: Simpson, Eric L., et al.
Publicado: (2021)

Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate‐to‐severe atopic dermatitis: an analysis of patient‐reported outcomes
por: Cork, M.J., et al.
Publicado: (2021)

The Efficacy and Safety of Abrocitinib as a Treatment Option for Atopic Dermatitis: A Short Report of the Clinical Data
por: Napolitano, Maddalena, et al.
Publicado: (2021)

Kinetic‐Pharmacodynamic Model of Platelet Time Course in Patients With Moderate‐to‐Severe Atopic Dermatitis Treated With Oral Janus Kinase 1 Inhibitor Abrocitinib
por: Soto, Elena, et al.
Publicado: (2020)

Economic impact of abrocitinib monotherapy and combination therapy in patients with moderate-to-severe atopic dermatitis: Results from JADE MONO-2 and JADE COMPARE
por: Gooderham, Melinda J., et al.
Publicado: (2021)

A Case of Perioral Dermatitis Successfully Treated with Abrocitinib
por: Teng, Yan, et al.
Publicado: (2023)

Abrocitinib 100 mg versus 200 mg for atopic dermatitis: a meta-analysis of randomized controlled trials
por: Wang, Junqiao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_b7sdlflf4pud4innn1sjkcdvvi